Drug Update
9 min read

New FDA-Approved Products October 2026

Written by
PharmPix
Published on
November 17, 2026

New Molecular Entity

Hovilpri (pritelivir) tablets, for oral use

FDA-Approved Indication

Treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection in immunocompromised adults that is refractory, with or without documented resistance, to acyclovir, valacyclovir, or famciclovir.

Dosage & Administration

400 mg orally on Day 1, followed by 100 mg orally once daily until HSV lesions have healed.

Dosage Forms & Strengths

Tablets: 100 mg.

Warnings & Precautions

  • Drug interactions with certain acid-reducing agents

Common Adverse Reactions

Headache.

Drug Interaction

  • Proton pump inhibitors
  • H2-receptor antagonists
  • Antacids

Clinical Studies

The approval came from PRIOH-1 Part C, a Phase 3, randomized, open-label, comparator-controlled superiority trial in 101 immunocompromised adults with mucocutaneous HSV infection refractory to acyclovir, valacyclovir, or famciclovir. Patients received Hovilpri or investigator’s choice of IV foscarnet, IV/topical cidofovir, or 5% topical imiquimod. The primary endpoint was complete lesion healing during treatment through Day 28. Hovilpri achieved a response rate of 63% versus 34% with one of the other medications (adjusted treatment difference 28.4%; P=0.0047).

Place in Therapy

Hovilpri offers a new oral treatment option, offering an alternative to IV therapies. Pritelivir inhibits the HSV helicase-primase complex and has a mechanism distinct from currently available antiviral therapies targeting viral DNA polymerase. The novel mechanism offers activity against acyclovir- and foscarnet-resistant HSV strains.

‍

Hibsago (bepirovirsen) injection, for subcutaneous use

FDA-Approved Indication

In combination with nucleos(t)ide analog reverse transcriptase inhibitor (NrtI) therapy for treatment of chronic hepatitis B virus (HBV) infection in adult patients without cirrhosis who have been on NrtI therapy for at least 6 months and have suppressed HBV DNA, and who have HBV surface antigen (HBsAg) levels less than or equal to 3,000 IU/mL as determined by an FDA-authorized test.

Dosage & Administration

300 mg subcutaneously twice weekly during Weeks 1 and 2 followed by 300 mg once weekly during Weeks 3 through 24.  

Dosage Forms & Strengths

Injection: 150 mg/mL solution in a single-dose prefilled syringe.

Contraindication(s)

  • Patients with acute hepatic impairment or cirrhosis with mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C).
  • Patients with platelet count <100 × 10⁹/L prior to treatment initiation.

Common Adverse Reactions

Injection site reactions, pyrexia, fatigue, headache.

Drug Interaction

  • Anticoagulants, antiplatelets or drugs that decrease platelet count
  • Drugs that impair renal function
  • Peginterferon alfa-2a

Warnings & Precautions

  • BBW: On-Treatment Hepatic Flares and Thrombocytopenia
  • Worsening Renal Function
  • Serious Inflammatory and Immune Adverse Reactions
  • Serious Adverse Reaction with Improper Administration
  • Post-Treatment Exacerbations of HBV Infection after Discontinuation
  • Risk of HIV-1 Virologic Failure in Patients with HBV/HIV-1 Coinfection

Clinical Studies

The approval came from B-Well 1 and B-Well 2, two Phase 3, randomized, double-blind, placebo-controlled trials. Patients were randomized 2:1 to receive Hibsago or placebo for 24 weeks in addition to background NrtI therapy. At 24 weeks after eligible patients discontinued NrtI therapy, sustained HBV DNA suppression with undetectable HBsAg was achieved in 20% vs 0% in B-Well 1 and 19% vs 0% in B-Well 2 for Hibsago versus placebo, respectively.  

Place in Therapy

Hibsago represents a novel treatment approach for selected adults with chronic hepatitis B whose HBV DNA is already suppressed with NrtI therapy. It is the first antisense oligonucleotide approved for chronic hepatitis B. Hibsago is administered for 24 weeks in addition to background NrtI therapy, rather than as a stand-alone treatment, and its use is limited to a defined noncirrhotic population requiring additional laboratory monitoring.

‍

New Formulations, Combinations, and Line Extensions

Weltruza (olanzapine) extended-release suspension, for subcutaneous use

FDA-Approved Indication

Treatment of schizophrenia in adults.

Dosage & Administration

318 mg, 425 mg, or 531 mg subcutaneously once monthly, based on the corresponding oral olanzapine dose.

Dosage Forms & Strengths

Powder for extended-release injectable suspension for subcutaneous use only: 318 mg, 425 mg, and 531 mg.

Warnings & Precautions

  • BBW: Increased Mortality in Elderly Patients with Dementia-Related Psychosis
  • Post-Injection Delirium/Sedation Syndrome
  • Neuroleptic Malignant Syndrome
  • Drug Reaction with Eosinophilia and Systemic Symptoms
  • Metabolic Changes
  • Tardive Dyskinesia
  • Orthostatic Hypotension
  • Leukopenia, Neutropenia, and Agranulocytosis
  • Seizures
  • Potential for Cognitive and Motor Impairment
  • Anticholinergic (antimuscarinic) Effects
  • Hyperprolactinemia
  • Laboratory Tests

Common Adverse Reactions

Weight increased, somnolence, headache, constipation, and injection site reactions (induration, pain, erythema, pruritus, swelling).

Use In Specific Populations

  • Pregnancy

Drug Interaction

  • Strong CYP1A2 Inducers and Inhibitors  
  • Centrally Acting Drugs and Alcohol
  • Anticholinergic Drugs
  • Antihypertensive Agents
  • Levodopa and Dopamine Agonists

Clinical Studies

The approval came from the phase 3 SOLARIS trial, a multinational, randomized, double-blind, placebo-controlled study in 675 patients with an acute exacerbation of schizophrenia. Patients were randomized 1:1:1:1 to Weltruza 318 mg, 425 mg, 531 mg, or placebo for 8 weeks, followed by a 48-week safety period. At Week 8, all three doses significantly improved PANSS total scores versus placebo, with treatment differences of −9.75, −11.27, and −9.76 points, respectively. Significant improvements were also observed in CGI-S and PSP scores across all three doses.

Place in Therapy

Weltruza is the first and only once-monthly subcutaneous olanzapine LAI for adults with schizophrenia. It does not require a loading dose, oral supplementation, nor post-injection monitoring. Although post-injection monitoring is not required, Weltruza retains the class Boxed Warning for increased mortality in elderly patients with dementia-related psychosis.

‍

New Biosimilars

Drug Name Reference Product Additional Information Estimated Availability Date*
Lucamzi (ranibizumab-blrz) Lucentis Lucamzi is the fifth FDA-approved biosimilar to Lucentis. 2027

*Note: The estimated availability date is subject to change based on various legal factors.

‍

New FDA-Approved Products

Other Notable Approvals

Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) solution for intramuscular injection

  • To reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis.

Yulzety (rivaroxaban) oral suspension

  • For the treatment or prevention of venous thromboembolic events, including DVT, PE, stroke/systemic embolism associated with nonvalvular atrial fibrillation, and VTE in eligible adult and pediatric patients.

Axycis (cisplatin) injection, for intravenous use

  • [1] Advanced testicular cancer; [2] Advanced ovarian cancer; [3] Advanced bladder cancer.

Evoxac (cevimeline hydrochloride) oral solution

  • For the treatment of symptoms of dry mouth in adults with Sjögren’s disease.

New First-Time Generic Approvals

First-Time Generics are the first generic forms of brand name drugs. The generic version is formulated to work in the same way as the brand-name product and provides the same clinical benefit.

Product Manufacturer Generic For Indication(s) Estimated Availability Date*
Estradiol-Levonorgestrel Transdermal Patch Weekly 0.045-0.015 MG/DAY Zydus Pharmaceuticals Inc. Climara Pro Vasomotor Symptoms due to Menopause; Prevention of Postmenopausal Osteoporosis Q4 2026

*Note: The estimated availability date is subject to change based on various legal factors.

New FDA-Approved Indications for Existing Drugs

The following table contains drugs that have gained FDA approval for the treatment of additional diseases or conditions.

Product Name Previous Indication(s) New Indication(s)
Jaypirca (pirtobrutinib) [1] Mantle cell lymphoma; [2] Relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma Adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion
Rhapsido (remibrutinib) Adult patients who remain symptomatic despite use of H1 antihistamine for the treatment of chronic spontaneous urticaria Adult patients who remain symptomatic despite use of H1 antihistamine for the treatment of symptomatic dermographism
Tukysa (tucatinib) [1] Unresectable or metastatic colorectal cancer; [2] In combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting In combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment
Tecentriq (atezolizumab) & Tecentriq Hybreza (atezolizumab/hyaluronidase-tqjs) [1] Non-small cell lung cancer; [2] Small cell lung cancer; [3] Hepatocellular carcinoma; [4] Melanoma; [5] Alveolar soft part sarcoma; [6] Muscle invasive bladder cancer In combination with a fluoropyrimidine and oxaliplatin, for the adjuvant treatment of patients with Stage III mismatch repair deficient (dMMR) colon cancer
Anktiva (nogapendekin alfa inbakicept-pmln) In combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors In combination with BCG for the treatment of adult patients with BCG-unresponsive NMIBC
Enspryng (satralizumab-mwge) Treatment of neuromyelitis optica spectrum disorder in adult patients who are anti-aquaporin-4 antibody positive Treatment of thyroid eye disease (TED) regardless of TED activity or duration in adult patients
Ryzumvi (phentolamine mesylate) Pharmacologically-induced mydriasis Treatment of presbyopia in adults
Jemperli (dostarlimab-gxly) [1] Mismatch repair deficient recurrent or advanced solid tumors; [2] Endometrial cancer Adult patients with Stage II/III, locally advanced rectal cancer that is microsatellite instability-high (MSI-H) or dMMR, as determined by an FDA-authorized test for solid tumors
Ultomiris (ravulizumab-cwvz) [1] Paroxysmal nocturnal hemoglobinuria; [2] Atypical hemolytic uremic syndrome; [3] Generalized myasthenia gravis; [4] Neuromyelitis optica spectrum disorder To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression
Awiqli (insulin icodec-abae) To improve glycemic control in adults with type 2 diabetes mellitus In adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus
Talzenna (talazoparib) [1] In combination with enzalutamide for the treatment of adult patients with metastatic androgen pathway modulation-resistant prostate cancer with homologous recombination repair gene mutations, as detected by an FDA-authorized test; [2] BRCA-mutated HER2-negative locally advanced or metastatic breast cancer In combination with enzalutamide for the treatment of adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations, as detected by an FDA-authorized test
Ilumya (tildrakizumab-asmn) Moderate-to-severe plaque psoriasis Active psoriatic arthritis in adult patients
Velphoro (sucroferric oxyhydroxide) For the control of serum phosphorus levels in adult and pediatric patients 9 years of age and older with chronic kidney disease on dialysis For the control of serum phosphorus levels in adult and pediatric patients 6 years of age and older with chronic kidney disease on dialysis

‍

Drug Pipeline

Denecimig

Estimated Launch Date: Mid 2027

Overview

Dencemig (Mim8) is an investigational, next-generation, subcutaneous factor VIIIa (FVIIIa)-mimetic bispecific antibody being evaluated for routine prophylaxis to prevent or reduce bleeding episodes in adult and pediatric patients with hemophilia A, with or without factor VIII inhibitors. Hemophilia A is characterized by a deficiency of factor VIII, which impairs the normal blood-clotting process. Mim8 is designed to bridge activated factor IX (FIXa) and factor X (FX), mimicking the normal activity of FVIIIa and enhancing the activation of FX to restore effective blood clotting. Unlike factor VIII replacement therapy, Mim8 provides FVIIIa-like activity without replacing the missing factor VIII protein. If approved, Mim8 would provide a subcutaneous prophylactic treatment option for patients with hemophilia A, regardless of inhibitor status.

Clinical Studies

The clinical development program for dencemig includes the pivotal Phase 3 FRONTIER2 and FRONTIER3 studies and the FRONTIER4 open-label extension study. FRONTIER2 evaluated once-weekly (QW) and once-monthly (QM) denecimig prophylaxis in adult and pediatric patients. Over 52 weeks, both regimens provided sustained bleed protection. Among patients previously receiving on-demand treatment, the estimated mean annualized bleeding rate (ABR) for treated bleeds was 0.57 with QW and 0.20 with QM denecimig, compared with 15.76 with continued on-demand treatment, representing reductions of 96.4% and 98.7%, respectively. FRONTIER3 evaluated QW and QM denecimig in children younger than 12 years with hemophilia A, with or without inhibitors. Over 52 weeks, the mean ABR was 0.42 with QW and 0.25 with QM dosing, and 81.6% and 87.5% of patients, respectively, experienced no treated bleeding episodes. The FRONTIER4 open-label extension study evaluated once-every-two-weeks (Q2W) prophylaxis and the long-term safety of QW, Q2W, and QM dosing. In an interim analysis of patients receiving Q2W denecimig, the estimated mean ABR for treated bleeding episodes was 0.4, the median ABR was 0, and 84% of patients experienced no treated bleeding episodes.

Place in Therapy  

Dencemig would become the first FVIIIa mimetic to offer flexible once-weekly (QW), once-every-two-weeks (Q2W), and once-monthly (QM) dosing in a single-use, prefilled pen. It would compete most directly with Hemlibra, the only other subcutaneous FVIIIa mimetic used for routine prophylaxis in adults and pediatric patients, including newborns, with hemophilia A with or without factor VIII inhibitors. Hemlibra offers similar dosing intervals but is supplied in single-dose vials that require the patient or caregiver to draw the prescribed dose into a syringe for subcutaneous administration. Dencemig would also compete with other subcutaneous non-factor prophylactic therapies, including Alhemo, Hympavzi, and Qfitlia, as well as factor VIII replacement products.

Generic Drug Pipeline

This section describes generics that may possibly be available on the market in the next month. The estimated availability date is subject to change based on various legal factors.

Generic Name Brand Name Brand Manufacturer
Pasireotide Diaspartate Signifor Recordati Rare Diseases
Vortioxetine HBr Trintellix Takeda Pharmaceuticals

‍

Share this post
Get Updates

The pharmacy benefit story moves fast. Keep the whole picture in view.

The Pharmacy Benefit Brief delivers perspective on cost, policy, and member protection. One email, once a month.

Colleagues discussing documents in a conference room
Bring Us Your Data

See the whole pharmacy picture.

Send us your claims data and we'll show you the avoidable cost and clinical risk hiding in it.